Erdafitinib Treatment in Metastatic Urothelial Carcinoma - Petros Grivas

Petros Grivas and Alicia Morgans join in a conversation about the recently FDA accelerated approval of erdafitinib in metastatic bladder cancer for tumors that exhibit mutations active isoforms of FGFR 2 and FGFR3.  Dr. Grivas discusses the companion biomarkers used in the determination of genomic sequencing of the tumor tissue exhibiting FGF reception mutations.  The indication for erdafitinib (package insert) is in patients where the genomic alternations are present and the patient. has previously been treated with platinum-based chemotherapy.    Dr. Grivas discusses the details of patient selection, treatment access and the details of FDA approved or cleared companion biomarker genomic tests.  

Biographies:
Petros Grivas, MD Ph.D., Associate Professor, Clinical Director of Genitourinary Cancers Program, University of Washington, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center

Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe